Ameriprise
EWTX icon

Ameriprise’s Edgewise Therapeutics EWTX Stock Holding History

Ameriprise’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.32M Sell
200,661
-1,636
-0.8% -$47.2K ﹤0.01% 2280
2025
Q4 		$5.02M Buy
+202,297
New +$4.06M ﹤0.01% 2431
2025
Q2 		– Sell
-13,167
Closed -$290K – 4012
2025
Q1 		$290K Sell
13,167
-9,417
-42% -$247K ﹤0.01% 3688
2024
Q4 		$603K Buy
+22,584
New +$719K ﹤0.01% 3452

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ameriprise's EWTX Position: Q1 2026 in Review

Ameriprise reduced its Edgewise Therapeutics (EWTX) stake by 0.81% in Q1 2026, selling an estimated $47.2K and leaving 200,661 shares worth $6.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2280.

Ameriprise first reported a position in EWTX in Q4 2024 and has held it in 4 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Ameriprise held 200,661 shares of Edgewise Therapeutics worth $6.32M as of Q1 2026.
  • Ameriprise sold 1,636 Edgewise Therapeutics shares in Q1 2026, an estimated $47.2K.
  • Edgewise Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2280 holding.
  • Ameriprise first reported a position in Edgewise Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.